Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC

Augmenting antibody response to EGF-depleting immunotherapy: Findings from a phase I trial of CIMAvax-EGF in combination with nivolumab in advanced stage NSCLC

BackgroundCIMAvax-EGF is an epidermal growth factor (EGF)-depleting immunotherapy which has shown survival benefit as a switch maintenance treatment after platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC). The primary objective of this trial is to establish the safety and re...

Full description

Bibliographic Details
Main Authors: Rachel Evans, Kelvin Lee, Paul K. Wallace, Mary Reid, Jason Muhitch, Askia Dozier, Circe Mesa, Patricia L. Luaces, Orestes Santos-Morales, Adrienne Groman, Carlos Cedeno, Aileen Cinquino, Daniel T. Fisher, Igor Puzanov, Mateusz Opyrchal, Christos Fountzilas, Tong Dai, Marc Ernstoff, Kristopher Attwood, Alan Hutson, Candace Johnson, Zaima Mazorra, Danay Saavedra, Kalet Leon, Agustin Lage, Tania Crombet, Grace K. Dy
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Oncology
Subjects:
immunotherapy
lung cancer
non-small cell lung cancer
immune checkpoint inhibitor
vaccine
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.958043/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.958043/full

Similar Items